Adalimumab in Patients with Active Noninfectious Uveitis | Zendy

Glenn J. Jaffe | Zendy; Andrew D. Dick | Zendy; Antoine P. Brézin | Zendy; Quan Dong Nguyen | Zendy; Jennifer E. Thorne | Zendy; Philippe Kestelyn | Zendy; Talin BarisaniAsenbauer | Zendy; Pablo Franco | Zendy; Arnd Heiligenhaus | Zendy; David K. Scales | Zendy; David Chu | Zendy; Anne Camez | Zendy; Nisha V. Kwatra | Zendy; Alexandra Song | Zendy; Martina Kron | Zendy; Samir Tari | Zendy; Eric B. Suhler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adalimumab in Patients with Active Noninfectious Uveitis

Author(s) -

Glenn J. Jaffe,

Andrew D. Dick,

Antoine P. Brézin,

Quan Dong Nguyen,

Jennifer E. Thorne,

Philippe Kestelyn,

Talin BarisaniAsenbauer,

Pablo Franco,

Arnd Heiligenhaus,

David K. Scales,

David Chu,

Anne Camez,

Nisha V. Kwatra,

Alexandra Song,

Martina Kron,

Samir Tari,

Eric B. Suhler

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1509852

Subject(s) - medicine , adalimumab , uveitis , adverse effect , glucocorticoid , intensive care medicine , dermatology , immunology , disease

Patients with noninfectious uveitis are at risk for long-term complications of uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid therapy. We conducted a trial to assess the efficacy and safety of adalimumab as a glucocorticoid-sparing agent for the treatment of noninfectious uveitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research